Skip to content

May 2026

DMT

What May 2026's 10 new studies found, synthesized from the papers below. All DMT research →

The synthesis

Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.

Research on DMT in May 2026 explored its neuroprotective potential in Parkinson's disease and stroke models, its effects on brain dynamics and autonomic arousal, and its subjective effects modulated by 5-HT1A receptors. Findings were mixed: DMT showed anti-inflammatory and neuroprotective effects in preclinical models, but also increased insomnia severity in a small observational study. The evidence is limited by small sample sizes, preclinical designs, and lack of clinical trials.

Confidence in the evidence

Low-Moderate
  • Multiple preclinical studies (article_ids 28213, 28215) provide mechanistic evidence but are not human trials.
  • Only one small observational study (article_id 28027) links DMT use to insomnia, with a very small DMT user subgroup (3.5% of 100).
  • Studies on brain dynamics (article_id 28163) and autonomic arousal (article_id 28195) are small (n=19) and open-label or semi-naturalistic.
  • The pharmacological study (article_id 28188) is a well-designed within-subjects RCT but with only 12 participants.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Traces of the Other – Are DMT Entities Real? DMT Phenomenology in the Framework of Conscious Realism 2026
Unclear

Proposes that DMT expands conscious experience by perturbing the perceptual interface, allowing interaction with normally imperceptible agents.

theoretical

Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat. 2026
Supports

Speech markers showed increased cognitive language and altered voice quality post-5-MeO-DMT, indicating a shift from external focus to introspection.

observational Sample size: 29

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality 2026
Unclear

Discusses DMT's relation to psychosis and therapy models, but no empirical data are provided.

theoretical

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease 2026
Supports

DMT reduced neuroinflammation and preserved neurons in a Parkinson's disease model, with behavioral improvements.

preclinical

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT 2026
Mixed

Acute DMT caused broad EEG microstate alterations across multiple frequency bands, while psilocybin microdosing had subtle effects; overlapping delta-band changes were noted.

observational

Multimodal autonomic arousal tracks dose-dependent affective dynamics during the acute effects of DMT 2026
Supports

DMT induced dose-dependent increases in autonomic arousal that tracked subjective emotional intensity, followed by gradual disengagement with pleasantness.

observational Sample size: 19

5-HT1A receptor blockade potentiates the subjective effects of DMT. 2026
Supports

5-HT1A receptor blockade with pindolol potentiated DMT-induced subjective effects with a moderate effect size.

RCT Sample size: 12

ABSTRACT NUMBER: ESOC2026YS125 DIMETHYLTRYPTAMINE INHIBITS SPREADING DEPOLARISATION IN BRAIN SLICES OF SIGMA-1 RECEPTORKNOCKOUT MICE 2026
Supports

DMT reduced spreading depolarization area in both wild-type and S1R-KO mice, with greater efficacy in S1R-KO mice.

preclinical Sample size: 12

0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study 2026
Opposes

DMT use was associated with higher rates of moderate-to-severe clinical insomnia (50.0% vs. 3.6% in non-DMT users).

observational Sample size: 100

N,N‐Dimethyltryptamine ( DMT ) Acutely Exposed to Mouse Ventral Tegmental Area I h ‐Negative Neurons Alters the Firing Rate and Conductance in a Sex‐Dependent Manner 2026
Mixed

High-concentration DMT increased firing and conductance in female but not male VTA neurons, while cytosolic calcium increased in both sexes.

preclinical

Points of agreement

  • DMT shows neuroprotective and anti-inflammatory effects in preclinical models of neurological disorders (Parkinson's disease, stroke).
  • DMT alters brain dynamics and autonomic arousal in a dose-dependent manner.
  • The subjective effects of DMT are modulated by serotonergic receptors, particularly 5-HT1A.

Conflicts

  • DMT was associated with increased insomnia severity in one observational study, but other studies did not assess sleep outcomes.
  • The preclinical stroke study found DMT more effective in sigma-1 receptor knockout mice, contrary to expectations that S1R mediates its effects.

Gaps

  • No human clinical trials on DMT's therapeutic efficacy for Parkinson's disease or stroke.
  • Durability of DMT's effects on brain dynamics and autonomic arousal is unknown.
  • The relationship between DMT use and insomnia is based on a very small sample and needs replication.
  • Sex-dependent effects of DMT on VTA neurons were observed only in preclinical models; human studies are lacking.
Browse these studies in the library